Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald boosted their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Trading Up 3.0 %

NASDAQ:VNDA opened at $4.75 on Friday. Vanda Pharmaceuticals has a 12-month low of $3.30 and a 12-month high of $6.75. The firm has a market cap of $276.44 million, a PE ratio of -59.38 and a beta of 0.77. The stock has a fifty day moving average price of $5.39 and a 200 day moving average price of $5.13.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million during the quarter. Equities analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VNDA. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals in the second quarter valued at approximately $39,000. SageView Advisory Group LLC acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at $34,000. SG Americas Securities LLC purchased a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $61,000. China Universal Asset Management Co. Ltd. raised its stake in Vanda Pharmaceuticals by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 4,387 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Vanda Pharmaceuticals in the second quarter valued at $75,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.